Choose a language and wait for the translated text.
The study tested the drug, laromestrocel, alongside standard surgery in 40 infants born with hypoplastic left heart syndrome, a severe birth defect where the left side of the heart is underdeveloped.
Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition | PharmaVoice
